Changing ARV Therapy in Patients with an Undetectable Viral Load: A Debate

About the Program

Program Overview

This presidential-style debate, featuring 2 nationally known speakers and a local moderator, will explore whether to change or stay the course with ARV therapy in a patient with an HIV RNA <50 c/mL. Included in the debate will be a discussion of recent data, including those from the 15th CROI, which indicate the potential positive and negative effects of changing ARV therapy in a fully suppressed patient.
This program is for health care providers who treat HIV-positive patients and there are no prerequisites.

Presented By:

Supported by an educational grant from Gilead Sciences

Learning Objectives

• Understand and be able to weigh in a clinical setting the risks and potential benefits of changing ARV therapy in a patient with an HIV RNA <50 copies/mL
• Understand and be able to discuss the differences between various ARV agents and regimens regarding adverse events, including short and long-term tolerability issues, morphologic and metabolic disturbances, and cardiovascular risk
• Describe clinical strategies to minimize ARV risks while maximizing the chance for long-term virologic suppression
• Share best practice information and data through interactions with leading clinicians

The Johns Hopkins University School of Medicine takes responsibliity for the content, quality, and scientific integrity of the CME activity 

Intended Audience

This activity is intended for physicians, physicians' assistants, and advanced practice nurses and other healthcare professionals involved in the treatment and management of patients with HIV infection. There are no prerequisites.

Accreditation Statement

The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Credit Designation Statement
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Course Directors

Joseph Confrancesco Jr, MD, MPH
Associate Professor of Medicine
Johns Hopkins School of Medicine
Director, Moore Clinic at Greenspring Station
Baltimore, Maryland

Calvin J. Cohen, MD, MS
Research Director, CRI New England,
Clinical Instructor, Harvard Medical School
Boston, Massachusetts

National Faculty

• Brian Boyle, MD, JD
  Director, ViralEd LLC
  Associate Professor of Medicine (Courtesy)
  Weill Medical College of Cornell University
  New York, NY
• Edwin DeJesus, MD
  Medical Director
  Orlando Immunology Center
  Orlando, FL
• Richard A. Elion, MD
  Associate Professor of Clinical Medicine
  George Washington University
  Washington, DC
• Graeme J. Moyle, MD, MB, BS
  Associate Director of HIV Research
  Chelsea & Westminster Hospital
  London, UK
• Trevor Hawkins, MD
  Associate Professor, University of New Mexico
  Medical Director, Southwest CARE Center
  Santa Fe, NM 
• Ian Frank, MD
  Associate Professor of Medicine
  Director, Antiretroviral Clinical Research
  University of Pennsylvania
  Philadelphia, PA
• Paul Sax, MD
  Clinical Director, Brigham and Women's Division
  Associate Professor of Medicine,
  Harvard Medical School
  Boston, MA

Instructions for Obtaining Continuing Medical Education Credit

Faculty Disclosure

Dr. Joseph Confrancesco's Disclosure Information:

• Consulting Agreements; Boehringer Ingelheim; GlaxoSmithKline; Abbott; Serono
• Speakers Bureau/Honorarium Agreements: GlaxoSmithKline; Gilead; Abbott

Dr. Calvin Cohen's Disclosure Information:

• Sources of Funding for Research: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Roche; Pfizer; Tibotec.
• Consulting Agreements: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Roche; Pfizer; Tibotec.
• Speakers' Bureau/Honorarium Agreements: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Roche; Pfizer; Tibotec; Virco.
• Financial Interests/Stock Ownership: None.
• Other: ViralEd, LLC.

Dr. Brian Boyle's Disclosure Information:

• Sources of Funding for Research: None
• Consulting Agreements: None
• Speakers' Bureau/Honorarium Agreements: None
• Financial Interests/Stock Ownership: None.
• Other: ViralEd, LLC.

Dr. Edwin DeJesus' Disclosure Information:

• Sources of Funding for Research: Boehringer Ingelheim; Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Roche; Pfizer; Tibotec; Merck; Schering Plough.
• Consulting Agreements: Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Roche; Vertex.
• Speakers' Bureau/Honorarium Agreements: Boehringer Ingelheim; Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Roche; Pfizer; Tibotec; Schering Plough.
• Financial Interests/Stock Ownership: None.

Dr. Richard A. Elion's Disclosure Information:

• Sources of Funding for Research: Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Incyte; Tibotec.
• Consulting Agreements: Bristol-Myers Squibb Company; Gilead Sciences, Inc.; GlaxoSmithKline; Incyte; Panacos.
• Speakers' Bureau/Honorarium Agreements: None.
• Financial Interests/Stock Ownership: None.
• Other: ViralEd, LLC.

Dr. Graeme Moyle's Disclosure Information:

• Sources of Funding for Research: Abbott; Arnomed; Ardea; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec.
• Consulting Agreements: Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Panacos; Tobira; Tibotec.
• Speakers' Bureau/Honorarium Agreements: Bristol-Myers Squibb; Boehringer-Ingelheim; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec.
• Financial Interests/Stock Ownership: None.
• Other: ViralEd, LLC.

Dr. Trevor Hawkin's Disclosure Information:

• Sources of Funding for Research: Gilead; GlaxoSmithKline; Tibotec; Taimed; Pfizer.
• Consulting Agreements: Bristol-Myers Squibb; Gilead; Tibotec; Monogram.
• Speakers' Bureau/Honorarium Agreements: Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Monogram; Pfizer; Tibotec.
• Financial Interests/Stock Ownership: None.

Dr. Ian Frank's Disclosure Information:

• Sources of Funding for Research: Bavarian Nordic; Merck; Tibotec.
• Consulting Agreements: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec.
• Speakers' Bureau/Honorarium Agreements: Abott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Tibotec.
• Financial Interests/Stock Ownership: None.
• Other: None. 

Dr. Paul Sax's Disclosure Information:

• Sources of Funding for Research: Bristol-Myers Squibb; Merck; Pfizer.
• Consulting Agreements: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline.
• Speakers' Bureau/Honorarium Agreements: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Tibotec; Virco.
• Financial Interests/Stock Ownership: None.
• Other: None.

View Online Seminar

 

The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.